Data-Driven Air-Fuel Path Control Design for Robust RCCI Engine Operation

Reactivity controlled compression ignition (RCCI) is a highly efficient and clean combustion concept, which enables the use of a wide range of renewable fuels. Consequently, this promising dual fuel combustion concept is of great interest for realizing climate neutral future transport. RCCI is very sensitive for operating conditions and requires advanced control strategies to guarantee stable and safe operation. For real-world RCCI implementation, we face control challenges related to transients and varying ambient conditions. Currently, a multivariable air–fuel path controller that can guarantee robust RCCI engine operation is lacking. In this work, we present a RCCI engine controller, which combines static decoupling and a diagonal MIMO feedback controller. For control design, a frequency domain-based approach is presented, which explicitly deals with cylinder-to-cylinder variations using data-driven, cylinder-individual combustion models. This approach enables a systematic trade-off between fast and robust performance and gives clear design criteria for stable operation. The performance of the developed multivariable engine controller is demonstrated on a six-cylinder diesel-E85 RCCI engine. From experimental results, it is concluded that the RCCI engine controller accurately tracks the five desired combustion and air path parameters, simultaneously. For the studied transient cycle, this results in 12.8% reduction in NOx emissions and peak in-cylinder pressure rise rates are reduced by 3.8 bar/deg CA. Compared to open-loop control, the stable and safe operating range is increased from 25 ∘C up to 35 ∘C intake manifold temperature and maximal load range is increased by 14.7% up to BMEP = 14.8 ba

Rethinking science communication in a changing landscape

Science communication continues to grow, develop and change, as a practice and field of research. The boundaries between science and the rest of society are blurring. Digitalization transforms the public sphere. This JCOM special issue aims to rethink science communication in light of the changing science communication landscape. How to characterize the emerging science communication ecosystem in relation to the introduction of new media and actors involved? What new practices are emerging? How is the quality of science communication maintained or improved? We present a selection of papers that provide different perspectives on these questions and challenges

Crafting the future of the artificial womb - speculative design as a tool for public engagement with emerging technologies

This study aimed to characterise the potential of speculative design in public engagement with emerging technologies. Current initiatives in public engagement have important drawbacks, such as the focus on quantifiable impacts, abstract reasoning and difficulties in imagining potential futures. Speculative design is considered a promising tool for public engagement because of its ability to open up dialogues about the societal implications of emerging technologies. Realising its potential depends on a thorough understanding of the reflective practices induced by speculative design. In this study we identified enabling factors for reflective practices to unfold and 3 ways of questioning human-technology relations, namely through scenarios, stereotypes and lived experiences. Our findings show that speculative design encourages imagining futures and facilitates reflection on qualitative impacts in various forms of knowledge by providing thought-provoking prospects. The medium has shortcomings, however. For participants to take on the role of creative moral agents the design needs to tread the fine line between activating them through ambiguity and informing them. Comparing our findings with pragmatist ethics, we show how speculative design can put into practice the four most prominent features of pragmatist democratic ethical deliberation.</p

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice

Objective. To evaluate the effectiveness and safety of adalimumab in patients with rheumatoid arthritis (RA) who previously discontinued tumour necrosis factor (TNF) antagonists for any reason in clinical practice. Methods. ReAct (Research in Active Rheumatoid Arthritis) was a large, open-label trial that enrolled adults with active RA who had previously been treated with traditional disease-modifying anti-rheumatic drugs or biological response modifiers. Patients selfadministered adalimumab 40 mg subcutaneously every other week for 12 weeks and were allowed to enter an optional long-term extension phase. Measures of adalimumab effectiveness included American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) response criteria, Disease Activity Score 28 (DAS28) and the Health Assessment Questionnaire Disability Index (HAQ DI). Results. Of 6610 patients, 899 had a history of etanercept and/or infliximab therapy; these patients experienced substantial clinical benefit from adalimumab treatment. At week 12, 60% of patients had an ACR20 and 33% had an ACR50 response; 76% had a moderate and 23% had a good EULAR response. In addition, 12% achieved a DAS28 < 2.6, indicating clinical remission, and 13% achieved a HAQ DI score < 0.5. The allergic adverse event rate, regardless of relationship to adalimumab, was 6.5/100-patient-years (PYs) in previously TNF antagonist-exposed patients and 4.3/100-PYs in TNF antagonist naive patients. A multiple regression analysis indicated no statistically significantly increased risk of serious infections in patients who received prior TNF antagonists compared with TNF antagonist naive patients. Conclusion. In typical clinical practice, adalimumab was effective and well-tolerated in patients with RA previously treated with etanercept and/or infliximab

Proporción diaria de alimento del diablillo antártico (pleuragramma antarcticum boulenger, 1902) en el este del mar de weddell

[EN] The daily ration of Pleuragramma antarcticum in the Eastern Weddell Sea was investigated from midwater and bottom trawl samples collected in the Antarctic in the summer of 1998. Using a gastric evacuation model that takes into account Weddell Sea temperature below zero and information on the prey type daily ration estimates were: 1.133% BW for immature fish of 10-16 cm and 0.484% BW for mature fish of 17-24 cm. The low daily ration intake was influenced by the low temperatures that limited the rate of gastric evacuation. This model seems more realistic than results from the classic Elliot & Persson and Eggers models that are also used in this paper, since their assumptions on feeding regularity are more rigid and they do not consider data of energy density of the prey[ES] La ración diaria de alimento de Pleuragramma antarcticum en el mar de Weddell es investigada en muestras de arrastres de fondo y pelágicas recogidas durante diferentes horas del día en el verano antártico de 1998. Utilizando un modelo de evacuación gástrica que tiene en cuenta la temperatura bajo del Mar de Weddell e información sobre el tipo de presa, las estimaciones de consumo diario fueron: 1.133% BW para peces inmaduros entre 10 -16 cm y 0.484% BW para peces maduros entre 17-24 cm. La baja ración diaria ingerida estuvo influida por las bajas temperaturas que limitan la tasa de evacuación gástrica. Este modelo parece más realista que los resultados de los modelos clásicos de Elliot & Persson and Eggers también empleados, ya que sus asunciones sobre su periodicidad de alimentación son más rígidas y no consideran datos de densidad energética de las presasThis work was conducted under the SCAR EASIZ programme, and was supported by the Alfred Wegener Institute and the Spanish Antarctic ProgrammePeer reviewe

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions

International audienceObjectives: To evaluate the effectiveness of adalimumab in patients with psoriatic arthritis (PsA) and identify predictors of good clinical response for joint and skin lesions. Methods: Patients received adalimumab 40 mg every other week in addition to standard therapy in this prospective, 12-week, open-label, uncontrolled study. Four definitions of good clinical response were used: >= 50% improvement in American College of Rheumatology response criteria (ACR50), good response according to European League Against Rheumatism (EULAR) guidelines, a >= 3-grade improvement in Physician Global Assessment of psoriasis (PGA) and a >= 50% improvement in the Nail Psoriasis Severity Index (NAPSI). Response predictors were determined by logistic regression with backward elimination (selection level was 5%). Results: Of 442 patients, 94% completed 12 weeks of treatment. At week 12, 74%, 51% and 32% of the patients had achieved ACR20, 50 and 70, respectively; 87% and 61% experienced moderate and good responses according to EULAR criteria, respectively. The percentage of patients with PGA results of "clear/almost clear'' increased from 34% (baseline) to 68%. The mean NAPSI score was reduced by 44%. No new safety signals were detected. A lower Health Assessment Questionnaire Disability Index (HAQ-DI) score, greater pain assessment, male sex and absence of systemic glucocorticoid therapy were strongly associated with achievement of ACR50 and good response according to EULAR criteria. In addition, greater C-reactive protein concentration and polyarthritis predicted ACR50, and non-involvement of large joints predicted a good response according to EULAR criteria. Conclusions: Adalimumab was effective in patients with PsA. Lower impairment of physical function, greater pain, male sex and no systemic treatment with glucocorticoids were factors that increased the chance of achieving a good clinical response

Taking stock and re-examining the role of science communication

Eight science communication research projects have been funded by the European Commission since 2018. These projects are a response to one of the European Commission's 'Science with and for Society' (SwafS) funding calls ¿ 'SwafS-19: Taking stock and re-examining the role of science communication.' Together these projects have received almost ¿10 million in research funding, and each has been affected to some extent by the COVID-19 global pandemic. This paper provides an overview of the eight projects, how they adapted to the challenges caused by the pandemic, and the subsequent implications for science communication policy and research funding

Assessment of the cortisol awakening response: Real-time analysis and curvilinear effects of sample timing inaccuracy

The cortisol awakening response (CAR) is typically measured in the domestic setting. Moderate sample timing inaccuracy has been shown to result in erroneous CAR estimates and such inaccuracy has been shown partially to explain inconsistency in the CAR literature. The need for more reliable measurement of the CAR has recently been highlighted in expert consensus guidelines where it was pointed out that less than 6% of published studies provided electronic-monitoring of saliva sampling time in the post-awakening period. Analyses of a merged data-set of published studies from our laboratory are presented. To qualify for selection, both time of awakening and collection of the first sample must have been verified by electronic-monitoring and sampling commenced within 15 min of awakening. Participants (n = 128) were young (median age of 20 years) and healthy. Cortisol values were determined in the 45 min post-awakening period on 215 sampling days. On 127 days, delay between verified awakening and collection of the first sample was less than 3 min (‘no delay’ group); on 45 days there was a delay of 4–6 min (‘short delay’ group); on 43 days the delay was 7–15 min (‘moderate delay’ group). Cortisol values for verified sampling times accurately mapped on to the typical post-awakening cortisol growth curve, regardless of whether sampling deviated from desired protocol timings. This provides support for incorporating rather than excluding delayed data (up to 15 min) in CAR analyses. For this population the fitted cortisol growth curve equation predicted a mean cortisol awakening level of 6 nmols/l (±1 for 95% CI) and a mean CAR rise of 6 nmols/l (±2 for 95% CI). We also modelled the relationship between real delay and CAR magnitude, when the CAR is calculated erroneously by incorrectly assuming adherence to protocol time. Findings supported a curvilinear hypothesis in relation to effects of sample delay on the CAR. Short delays of 4–6 min between awakening and commencement of saliva sampling resulted an overestimated CAR. Moderate delays of 7–15 min were associated with an underestimated CAR. Findings emphasize the need to employ electronic-monitoring of sampling accuracy when measuring the CAR in the domestic setting